The potential pharma companies see in this type of therapy was demonstrated last year, when Juno signed a decade-long, billion-dollar deal with Celgene to develop CAR-T therapies. Hans Bishop ...

公告称，公司已与Juno建立紧密的合作关系 ... 公司必须能够利用其在CAR-T研发、制造及商业化方面的优势，以借助与百时美施贵宝这一现有关系 ...

智通财经APP讯，药明巨诺-B(02126)发布公告，公司于2025年3月19日与Juno(公司主要股东之一及关连人士)订立材料转让协议，据此，Juno向公司(或其指定联属公司)转让总价值不低于100万美元的若干载体，以换取公司同意Juno使用初步s ...

Juno Therapeutics could be set for a remarkable comeback in CAR-T therapy, after encouraging trial data on a new candidate suggests it could be prove to be the best in class. The Seattle-based ...

Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd. As of Jan. 31, 2024, there were more than 300 CAR T trials registered in China, surpassing ...